Skip to main content

Inpatient Double-Blind Placebo-Controlled Withdrawal Study of 3,4-Diaminopyridine Base (3,4-DAP) in Subjects with Known Lambert-Eaton Myasthenic Syndrome (LEMS) [JPC 3,4-DAPPER]

Research Grant
Duke Scholars

Administered By

Duke Clinical Research Institute

Awarded By

Jacobus Pharmaceutical Company, Inc.

Start Date

November 16, 2018

End Date

April 30, 2020
 

Administered By

Duke Clinical Research Institute

Awarded By

Jacobus Pharmaceutical Company, Inc.

Start Date

November 16, 2018

End Date

April 30, 2020